Churg-Strauss Syndrome (EGPA): Vasculitis Presentation, Diagnosis, and Treatment

Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly Churg-Strauss Syndrome, is a rare ANCA-associated vasculitis defined by the triad: asthma, eosinophilia, and necrotizing vasculitis of small/medium vessels.

Clinical Phases (Not Always Sequential)

  1. Allergic/Prodromal: Adult-onset asthma, allergic rhinitis, nasal polyps, sinusitis.
  2. Eosinophilic: Tissue infiltration — pulmonary infiltrates, eosinophilic gastroenteritis, pericarditis.
  3. Vasculitic: Systemic necrotizing vasculitis — neuropathy (mononeuritis multiplex), purpura, GI ischemia, cardiomyopathy, renal (less severe than GPA/MPA).

Diagnostic Criteria (ACR 1990 / Chapel Hill)

≥4 of 6: Asthma, Eosinophilia >10% or >1500/µL, Neuropathy, Pulmonary infiltrates (non-fixed), Paranasal sinus abnormality, Biopsy with extravascular eosinophils.

Workup

  • ANCA (p-ANCA/MPO positive in ~40%); CBC with differential, IgE, CRP/ESR
  • Imaging: CXR/CT (fleeting infiltrates), cardiac MRI (myocarditis), nerve conduction
  • Biopsy: Nerve, muscle, skin, lung — eosinophilic granulomas, necrotizing vasculitis

Treatment (Five-Factor Score Guides Intensity)

  • FFS=0 (No cardiac, GI, renal, ENT involvement, Age<65): Glucocorticoids alone (prednisone 1 mg/kg → taper).
  • FFS≥1: Glucocorticoids + Cyclophosphamide (induction) → Azathioprine/MMF (maintenance).
  • Refractory/Relapsing: Rituximab (non-inferior to CYC), Mepolizumab (anti-IL5, FDA-approved for EGPA), Benralizumab (emerging).
  • Adjuncts: Plasmapheresis (severe renal/cardiac), IVIG.

Prognosis

  • 5-year survival >85% with modern therapy.
  • Cardiac involvement = major mortality driver.
  • Relapses common (asthma, ENT, neuropathy); long-term low-dose GC ± steroid-sparing agent often needed.

Genetic Disorders - Related Articles